Pseudobulbar Affect in ALS: Dextromethorphan-Quinidine Against a Prolonged QTc
A patient with ALS-related pseudobulbar affect has the syndrome the only FDA-approved drug was built to treat — and a QTc on amiodarone that sits inside that same drug's labeled contraindication.
R.T., a 66-year-old man, taught middle school band for thirty-four years and still keeps a trumpet on a stand in his living room, though his hands no longer let him play it the way he used to. He was diagnosed with bulbar-onset ALS fourteen months ago, after a year of progressively slurred speech he'd first blamed on new dentures, and has been on riluzole since diagnosis. His wife brought up what she's started calling "the spells" at today's visit: several times a week now, he breaks into loud, uncontrollable laughing during conversations that aren't funny, or crying during a television commercial, each episode lasting a minute or two and leaving him more embarrassed than anything else — he says plainly that his mood in between the episodes hasn't changed, he just can't stop the reaction once it starts.
That description — an outburst disconnected from the underlying mood, stereotyped, and clearly incongruent with or disproportionate to what triggered it — is the clinical signature of pseudobulbar affect, not a mood disorder: corticobulbar and cerebellar circuits that normally dampen an emotional motor response are disrupted by the same degeneration driving his bulbar symptoms, so the expression fires without the feeling driving it. He scores 21 on the CNS-LS (Center for Neurologic Study–Lability Scale), well above the range associated with clinically significant lability. He is also, separately, five years out from an atrial fibrillation diagnosis, rate-controlled on amiodarone since a failed ablation attempt — a fact that turns out to matter directly to which drug treats his lability, not just an item on his problem list. His most recent ECG, done for amiodarone monitoring three months ago, showed a QTc of 462ms — above the 450ms ceiling conventionally applied to men, and so inside the range the label of the drug now under discussion names as an outright contraindication rather than a caution.
Dextromethorphan-quinidine is the only FDA-approved treatment for pseudobulbar affect, and its pivotal STAR trial (Pioro et al., Annals of Neurology, 2010) enrolled ALS and MS patients whose CNS-LS was at least 13 — at 21 he sits well inside the population that trial actually studied, not an extrapolation from it. But the "quinidine" in the name is not a coincidence of formulation: it is there because it inhibits CYP2D6, the enzyme that would otherwise clear dextromethorphan almost immediately, and it prolongs the QT interval in its own right. He matches the trial on the symptom that would qualify him and fails the label on the number that would exclude him.
ALS clinic, weighing the QTc
Dextromethorphan-quinidine is what actually treats this. The pivotal trial — Pioro and colleagues' randomized, placebo-controlled study published in Annals of Neurology in 2010, the one that led to FDA approval — enrolled patients with ALS or MS pseudobulbar affect specifically, and found real, significant reductions in CNS-LS score against placebo. He isn't an extrapolated population; he's the population the drug was built and tested for. Nothing else carries that specific an evidence base for this specific syndrome.
I recognize the QTc number, and I know where it sits relative to the label. I'm not dismissing that — I'm saying the number we're all reasoning from is three months old, and I'd rather establish whether it still describes him than treat a stale value as having settled his eligibility.
I'd stop before that trial gets weighed against anything, because this isn't a balance — it's an exclusion. A prolonged QT interval is a listed contraindication to dextromethorphan-quinidine, not a caution to be managed with monitoring, and 462ms in a man is prolonged. The ultra-low-dose quinidine isn't inert filler: it's a potent CYP2D6 inhibitor and independently QT-prolonging even at 10mg. In the label's own thorough-QT study the combination added a mean of roughly 7ms to QTcF in healthy volunteers — a modest number in isolation, and not a modest one on top of a patient already at 462 on amiodarone, one of the most QT-prolonging drugs still in routine use.
The trial evidence being real doesn't resolve whether it's usable for him. STAR reported no active-drug recipient exceeding a QTc of 480ms — reassuring for the patients it enrolled, and a poor guide to a man who starts 18ms below that ceiling before he takes a single dose. Efficacy data cannot be traded against a contraindication; the label doesn't offer that exchange.
There's a second problem underneath the QT one: amiodarone is itself a moderate CYP2D6 inhibitor. Adding quinidine on top of that doesn't predictably double the effect — it makes his dextromethorphan exposure genuinely hard to predict, in either direction, in a drug combination that was never studied together. I'd use sertraline instead, and I want to be honest about what that evidence is. It is real and it is randomized — Andersen and colleagues' placebo-controlled crossover of citalopram (Lancet, 1993), Brown and colleagues on fluoxetine (1998), and Burns and colleagues on sertraline itself (1999), which found a response in 13 of 14 patients against 9 of 14 on placebo. But all three were done in post-stroke emotionalism, not ALS, and the largest of them enrolled fourteen patients. That is a weaker evidence base than the one he's citing, extrapolated across a different underlying cause. It is also the only one of the two options he is actually eligible to receive.
I agree the contraindication is categorical, and I want to be careful about what that means here: it attaches to a measurement, and the measurement we're using is three months old. Amiodarone's QT effect isn't static across a patient's course. Get a same-day ECG before anything is decided — not to reopen the balance, but to establish whether the value that excludes him is actually his value today.
I'd push back slightly on treating 462 as settled fact. If the repeat confirms it, or comes in higher, the question closes and nobody needs to argue mechanism further. If it has fallen back below 450 — which happens, particularly if anything else QT-active has come off in the interim — then he is a different patient from the one being described tonight, and the discussion restarts on ground where the label permits it. Either way the answer comes from an ECG, not from us re-weighing a trial.
One thing I'd flag regardless of the result: if sertraline starts today and this is revisited later, that combination carries its own labeled serotonin-syndrome warning. Whatever happens with the QTc, dextromethorphan-quinidine would not simply be added on top of an SSRI without stopping to think about it.
Agreed: on the numbers currently on file he is contraindicated for dextromethorphan-quinidine, and the drug is not started. A same-day ECG is ordered, with cardiology reading it directly, on the narrow question of whether 462ms is still his value rather than as a risk-benefit exercise. Sertraline starts today regardless, at a low dose — it carries no meaningful QT or CYP2D6 concern and gives him some relief from the lability while the ECG question is settled.
Not agreed, and left open pending the result: what a lower reading would actually license. The Cardiologist would treat a QTc back under 450 as making him a genuinely different candidate, on the grounds that the contraindication is defined by the measurement and by nothing else. The Clinical Pharmacologist would still decline, holding that a man whose QT sits at the threshold on chronic amiodarone has no headroom for a second QT-prolonging agent even when a single reading permits it, and that the serotonin-syndrome warning attached to adding it on top of sertraline is a second reason not to go looking. Both agreed to revisit only after the repeat ECG, not to argue it further today.